Centerpoint Advisors’s Charles River Laboratories CRL Stock Holding History

Centerpoint Advisors’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-90	Closed	-$21K	–	433
2023 Q4	$21K	Hold	90	–	–	0.01%	225
2023 Q3	$18K	Hold	90	–	–	0.01%	241
2023 Q2	$19K	Hold	90	–	–	0.01%	259
2023 Q1	$18K	Hold	90	–	–	0.01%	266
2022 Q4	$20K	Hold	90	–	–	0.01%	203
2022 Q3	$18K	Hold	90	–	–	0.01%	187
2022 Q2	$19K	Hold	90	–	–	0.01%	193
2022 Q1	$26K	Hold	90	–	–	0.01%	180
2021 Q4	$34K	Hold	90	–	–	0.01%	150
2021 Q3	$37K	Buy	90 +10	+13%	+$4.15K	0.02%	138
2021 Q2	$30K	Buy	80 +30	+60%	+$10K	0.01%	151
2021 Q1	$14K	Hold	50	–	–	0.01%	151
2020 Q4	$12K	Buy	50 +25	+100%	+$5.95K	0.01%	154
2020 Q3	$6K	Buy	+25	New	+$5.19K	﹤0.01%	167

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Centerpoint Advisors's CRL Position: Q1 2024 in Review

Centerpoint Advisors sold out of Charles River Laboratories (CRL) in Q1 2024, closing a stake of 90 shares — an estimated $21K sold.

Centerpoint Advisors first reported a position in CRL in Q3 2020 and held it in 14 quarters. The position peaked at $37K in Q3 2021. 676 funds tracked by Wall St. Rank hold CRL as of Q1 2024.

Centerpoint Advisors reported no remaining Charles River Laboratories position as of Q1 2024 after selling out during the quarter.
Centerpoint Advisors sold 90 Charles River Laboratories shares in Q1 2024, an estimated $21K.
Centerpoint Advisors first reported a position in Charles River Laboratories in Q3 2020 and held it in 14 quarters.
Centerpoint Advisors's Charles River Laboratories position peaked at $37K in Q3 2021.
676 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2024.

Based on Centerpoint Advisors's 13F filing for Q1 2024, filed 2 May 2024.